Equities Analysts Offer Predictions for Omnicell, Inc.’s Q2 2024 Earnings (NASDAQ:OMCL)

Omnicell, Inc. (NASDAQ:OMCL) – Research analysts at Zacks Research dropped their Q2 2024 earnings per share estimates for shares of Omnicell in a research note issued on Wednesday, July 24th. Zacks Research analyst U. Biswas now forecasts that the company will post earnings of ($0.03) per share for the quarter, down from their previous estimate of $0.01. The consensus estimate for Omnicell’s current full-year earnings is $0.26 per share. Zacks Research also issued estimates for Omnicell’s FY2024 earnings at $0.18 EPS, Q2 2025 earnings at $0.12 EPS, FY2025 earnings at $0.51 EPS and Q2 2026 earnings at $0.09 EPS.

Omnicell (NASDAQ:OMCL) last posted its quarterly earnings data on Thursday, May 2nd. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.17. Omnicell had a positive return on equity of 2.41% and a negative net margin of 1.91%. The company had revenue of $246.15 million for the quarter, compared to the consensus estimate of $235.70 million.

Several other equities research analysts also recently issued reports on OMCL. StockNews.com downgraded Omnicell from a “buy” rating to a “hold” rating in a report on Tuesday, July 16th. Benchmark reiterated a “buy” rating and issued a $38.00 price target on shares of Omnicell in a report on Monday, July 15th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $42.20.

Omnicell Price Performance

OMCL stock opened at $29.29 on Friday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.13 and a current ratio of 2.38. Omnicell has a 52-week low of $25.12 and a 52-week high of $66.65. The stock’s 50 day moving average is $28.74 and its two-hundred day moving average is $29.20.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Nisa Investment Advisors LLC raised its position in Omnicell by 248.8% during the second quarter. Nisa Investment Advisors LLC now owns 1,402 shares of the company’s stock valued at $38,000 after buying an additional 1,000 shares during the period. EntryPoint Capital LLC increased its position in Omnicell by 121.2% in the 1st quarter. EntryPoint Capital LLC now owns 2,455 shares of the company’s stock worth $72,000 after purchasing an additional 1,345 shares during the last quarter. CWM LLC increased its position in Omnicell by 68.2% in the 2nd quarter. CWM LLC now owns 3,048 shares of the company’s stock worth $83,000 after purchasing an additional 1,236 shares during the last quarter. Benjamin Edwards Inc. increased its position in Omnicell by 36.4% in the 1st quarter. Benjamin Edwards Inc. now owns 3,253 shares of the company’s stock worth $95,000 after purchasing an additional 868 shares during the last quarter. Finally, Strs Ohio increased its position in Omnicell by 28.2% in the 4th quarter. Strs Ohio now owns 5,000 shares of the company’s stock worth $188,000 after purchasing an additional 1,100 shares during the last quarter. 97.70% of the stock is owned by institutional investors and hedge funds.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.